Lanean...
Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report
RATIONALE: Pyrotinib is a novel dual pan-ErbB receptor tyrosine kinase inhibitor, approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). However, there was still limited information regarding specific effect of pyrotinib on HER2-positiv...
Gorde:
| Argitaratua izan da: | Medicine (Baltimore) |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Wolters Kluwer Health
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7310977/ https://ncbi.nlm.nih.gov/pubmed/32569228 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000020809 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|